Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Compare

1,437 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

OCUL Analyst Ratings

Strong Buy

9 Buy

1 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Ocular

Therapeutix

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

OCUL Stock 12 Month Forecast

Average Price Target

$16.83

▲(36.61% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Ocular Therapeutix in the last 3 months. The average price target is $16.83 with a high forecast of $21.00 and a low forecast of $12.50. The average price target represents a 36.61% change from the last price of $12.32.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","22":"$22","9.25":"$9.25","13.5":"$13.5","17.75":"$17.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$21.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,9.25,13.5,17.75,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.92,12.618461538461538,13.316923076923077,14.015384615384615,14.713846153846154,15.412307692307692,16.11076923076923,16.80923076923077,17.50769230769231,18.206153846153846,18.904615384615383,19.603076923076923,20.301538461538463,{"y":21,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.92,12.297692307692307,12.675384615384615,13.053076923076922,13.43076923076923,13.808461538461538,14.186153846153845,14.563846153846153,14.94153846153846,15.319230769230767,15.696923076923076,16.074615384615385,16.45230769230769,{"y":16.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.92,11.964615384615385,12.009230769230768,12.053846153846154,12.098461538461539,12.143076923076922,12.187692307692307,12.232307692307693,12.276923076923078,12.321538461538461,12.366153846153846,12.410769230769231,12.455384615384615,{"y":12.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.07,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.82,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.77,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.14,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.53,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.11,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$21.00

Average Price Target$16.83

Lowest Price Target$12.50

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yi Chen

H.C. Wainwright

$15

Buy

21.75%

Upside

Reiterated

08/13/25

Promising Developments and Strategic Advancements Support Buy Rating for Ocular Therapeutix

Lachlan Hanbury Brown

William Blair

―

Buy

―

Reiterated

08/12/25

Ocular Therapeutix: Strategic Advancements and Market Potential Drive Buy Rating

Dex Genotek

TR | OpenAI - 4o

$12.5

Hold

1.46%

Upside

Reiterated

08/11/25

AI Generated ArticleAI Generated Article

Serge Belanger

Needham

$15

Buy

21.75%

Upside

Reiterated

08/06/25

Ocular Therapeutix (OCUL) PT Raised to $15 at NeedhamNeedham analyst Serge Belanger raised the price target on Ocular Therapeutix (NASDAQ: OCUL) to $15.00 (from $14.00) while maintaining a Buy rating.

Greg Harrison

Scotiabank

$22→$20

Buy

62.34%

Upside

Reiterated

08/06/25

Scotiabank Remains a Buy on Ocular Therapeutix (OCUL)

William Maughan

Clear Street

$18

Buy

46.10%

Upside

Reiterated

08/05/25

Clear Street reiterates Buy Rating on Ocular Therapeutix (OCUL)Clear Street analyst Bill Maughan reiterated a Buy rating and $18.00 price target on Ocular Therapeutix (NASDAQ: OCUL).

Tara Bancroft

TD Cowen

$14

Buy

13.64%

Upside

Reiterated

08/05/25

TD Cowen on Ocular Therapeutix (OCUL): SOL-1 Data In Q1:2026 Should Be Positive And Clinically RelevantTD Cowen analyst Tara Bancroft reiterated a Buy rating and $14.00 price target on Ocular Therapeutix (NASDAQ: OCUL).

Lisa Walter

RBC Capital

$17

Buy

37.99%

Upside

Reiterated

08/05/25

Ocular Therapeutix (OCUL) Receives a Buy from RBC Capital

Dane Leone

Raymond James

$19

Buy

54.22%

Upside

Reiterated

08/04/25

Raymond James Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)Raymond James analyst Dane Leone reiterated a Strong Buy rating and $19.00 price target on Ocular Therapeutix (NASDAQ: OCUL).

Biren Amin

Piper Sandler

$21

Buy

70.45%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX), Ocular Therapeutix (NASDAQ: OCUL) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Tazeen Ahmad

Bank of America Securities

$17

Buy

37.99%

Upside

Reiterated

05/19/25

Ocular Therapeutix (OCUL) Gets a Buy from Bank of America Securities

Jonathan Wolleben

Citizens JMP

$19

Buy

54.22%

Upside

Reiterated

04/23/25

Citizens JMP reiterates Market Outperform Rating on Ocular Therapeutix (OCUL)Citizens JMP analyst Jonathan Wolleben reiterated a Market Outperform rating and $19.00 price target on Ocular Therapeutix (NASDAQ: OCUL).

Colleen M. Kusy

Robert W. Baird

$17

Buy

37.99%

Upside

Reiterated

12/03/24

Baird reiterates Outperform Rating on Ocular Therapeutix (OCUL)Baird analyst Colleen Kusy reiterated an Outperform rating and $17.00 price target on Ocular Therapeutix (NASDAQ: OCUL).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yi Chen

H.C. Wainwright

$15

Buy

21.75%

Upside

Reiterated

08/13/25

Promising Developments and Strategic Advancements Support Buy Rating for Ocular Therapeutix

Lachlan Hanbury Brown

William Blair

―

Buy

―

Reiterated

08/12/25

Ocular Therapeutix: Strategic Advancements and Market Potential Drive Buy Rating

Dex Genotek

TR | OpenAI - 4o

$12.5

Hold

1.46%

Upside

Reiterated

08/11/25

AI Generated ArticleAI Generated Article

Serge Belanger

Needham

$15

Buy

21.75%

Upside

Reiterated

08/06/25

Greg Harrison

Scotiabank

$22→$20

Buy

62.34%

Upside

Reiterated

08/06/25

Scotiabank Remains a Buy on Ocular Therapeutix (OCUL)

William Maughan

Clear Street

$18

Buy

46.10%

Upside

Reiterated

08/05/25

Clear Street reiterates Buy Rating on Ocular Therapeutix (OCUL)Clear Street analyst Bill Maughan reiterated a Buy rating and $18.00 price target on Ocular Therapeutix (NASDAQ: OCUL).

Tara Bancroft

TD Cowen

$14

Buy

13.64%

Upside

Reiterated

08/05/25

Lisa Walter

RBC Capital

$17

Buy

37.99%

Upside

Reiterated

08/05/25

Ocular Therapeutix (OCUL) Receives a Buy from RBC Capital

Dane Leone

Raymond James

$19

Buy

54.22%

Upside

Reiterated

08/04/25

Raymond James Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)Raymond James analyst Dane Leone reiterated a Strong Buy rating and $19.00 price target on Ocular Therapeutix (NASDAQ: OCUL).

Biren Amin

Piper Sandler

$21

Buy

70.45%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX), Ocular Therapeutix (NASDAQ: OCUL) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Tazeen Ahmad

Bank of America Securities

$17

Buy

37.99%

Upside

Reiterated

05/19/25

Ocular Therapeutix (OCUL) Gets a Buy from Bank of America Securities

Jonathan Wolleben

Citizens JMP

$19

Buy

54.22%

Upside

Reiterated

04/23/25

Colleen M. Kusy

Robert W. Baird

$17

Buy

37.99%

Upside

Reiterated

12/03/24

Baird reiterates Outperform Rating on Ocular Therapeutix (OCUL)Baird analyst Colleen Kusy reiterated an Outperform rating and $17.00 price target on Ocular Therapeutix (NASDAQ: OCUL).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ocular Therapeutix

1 Month

xxx

Success Rate

15/35 ratings generated profit

Average Return

+2.77%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 42.86% of your transactions generating a profit, with an average return of +2.77% per trade.

3 Months

xxx

Success Rate

8/16 ratings generated profit

Average Return

+10.00%

reiterated a xxx

rating 9 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +10.00% per trade.

1 Year

Yi ChenH.C. Wainwright

Success Rate

16/21 ratings generated profit

Average Return

+51.56%

reiterated a buy rating 16 days ago

Copying Yi Chen's trades and holding each position for 1 Year would result in 76.19% of your transactions generating a profit, with an average return of +51.56% per trade.

2 Years

xxx

Success Rate

16/16 ratings generated profit

Average Return

+109.44%

reiterated a xxx

rating 9 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +109.44% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OCUL Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, OCUL has received 11 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. OCUL average Analyst price target in the past 3 months is 16.83.

Each month's total comprises the sum of three months' worth of ratings.

OCUL Financial Forecast

OCUL Earnings Forecast

Next quarter’s earnings estimate for OCUL is -$0.38 with a range of -$0.42 to -$0.34. The previous quarter’s EPS was -$0.39. OCUL beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 48.84% of the time in the same period. In the last calendar year OCUL has Outperformed its overall industry.

OCUL Sales Forecast

Next quarter’s sales forecast for OCUL is $14.48M with a range of $12.57M to $19.00M. The previous quarter’s sales results were $13.46M. OCUL beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 54.10% of the time in the same period. In the last calendar year OCUL has Outperformed its overall industry.

OCUL Stock Forecast FAQ

What is OCUL’s average 12-month price target, according to analysts?

Based on analyst ratings, Ocular Therapeutix Inc’s 12-month average price target is 16.83.

What is OCUL’s upside potential, based on the analysts’ average price target?

Ocular Therapeutix Inc has 36.61% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is OCUL a Buy, Sell or Hold?

Ocular Therapeutix Inc has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.

What is Ocular Therapeutix Inc’s price target?

The average price target for Ocular Therapeutix Inc is 16.83. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $21.00 ,the lowest forecast is $12.50. The average price target represents 36.61% Increase from the current price of $12.32.

What do analysts say about Ocular Therapeutix Inc?

Ocular Therapeutix Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of OCUL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

OCUL Analyst Ratings

OCUL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ocular Therapeutix

OCUL Analyst Recommendation Trends

OCUL Financial Forecast

OCUL Earnings Forecast

OCUL Sales Forecast

OCUL Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts